19-371 - Expanded Access to Voxelotor for Patients With Sickle Cell Disease Who Have No Alternative Treatment Options
Status: openAn Open-Label, Expanded Access Protocol for Patients with Sickle Cell Disease Who Have No Alternative Treatment Options
Sickle Cell Disease
Description
The purpose of this program is to provide early access to voxelotor for patients with sickle cell disease (SCD) who have exhausted alternative treatment options and are ineligible for actively-recruiting clinical trials of voxelotor.
Sponsors
This trial is sponsored by Global Blood Therapeutics.Interested in Clinical Trial?
Contact the Clinical Trial Coordinator
If you have questions get in touch with this Clinical Trial’s Coordinator by phone at (251) 471-7714 or by email at acsmith@health.southalabama.edu.
![Johnson Haynes]()
View ProfileJohnson Haynes, Jr., M.D.PulmonologistAssistant Dean of the Office of Diversity and Inclusion; Director of Comprehensive Sickle Cell Center; Professor of Internal Medicine
This link will open in a new tab or window.